Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRP78 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Notre Dame
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
GRP78 siRNA is a small interfering RNA (siRNA) designed to silence the expression of **Glucose-Regulated Protein 78 (GRP78)**, also known as **HSPA5**. GRP78 is a molecular chaperone located in the endoplasmic reticulum that plays a pivotal role in the unfolded protein response (UPR) and cell survival under stress. In various cancers, including pancreatic ductal adenocarcinoma (PDAC), GRP78 is frequently overexpressed and can relocate to the cell surface, where it promotes tumor progression, chemoresistance, and activation of the PI3K/AKT signaling pathway. By utilizing RNA interference to knock down GRP78 levels, this therapeutic approach aims to inhibit pro-survival signaling and sensitize resistant tumor cells to chemotherapy agents such as gemcitabine.
- Other names
- siRNA targeting GRP78HSPA5 siRNAHSPA-5 siRNAHSPA 5 siRNAglucose-regulated protein 78 siRNA
02
Targets
HSPA5 (Heat shock protein family A member 5)
Beyond the preview
Go deeper on GRP78 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRP78 siRNA.